Results 231 to 240 of about 26,552 (294)

Simplified Switching to Once‐Weekly Insulin Icodec Without an Initial One‐Time Additional Dose Versus Once‐Daily Insulin Glargine U100 in Basal Insulin‐Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7791-7801, September 2026.
ABSTRACT Aims ONWARDS 10 assessed switching from daily basal insulins to once‐weekly insulin icodec without a one‐time additional dose at first injection. Materials and Methods In this treat‐to‐target, open‐label, 26‐week, phase 3b trial, adults with basal‐insulin‐treated type 2 diabetes (T2D) with glycated haemoglobin [HbA1c] 7.0%–10.0% were ...
Julio Rosenstock, Chantal Mathieu, Joshua Buron Feinberg, Priyanka Rao, Cathrine Scavenius, Alice Y. Y. Cheng   +5 more
wiley   +1 more source

Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study. [PDF]

Diabetes Obes Metab
Engström A, Svanström H, Hviid A, Eliasson B, Gudbjörnsdottir S, Wintzell V, Hveem K, Jonasson C, Melbye M, Ueda P, Pasternak B.   +10 more
europepmc   +1 more source

Cardiovascular Outcomes in a SELECT‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS Database

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8057-8071, September 2026.
ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger, Josefine Fagerström, Håkan Nero, Thomas Cars, Maria K. Svensson, Anna Norhammar   +5 more
wiley   +1 more source

Aerobic Exercise Training Increases Circulating sRAGE in Adults With Type 2 Diabetes: Associations With Sheddase Regulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8157-8171, September 2026.
ABSTRACT Objective Soluble receptor for advanced glycation end‐products (sRAGE) and soluble Toll‐like receptor 4 (sTLR4) are circulating pattern recognition receptor isoforms implicated in inflammatory regulation in type 2 diabetes mellitus (T2DM). This study examined the effects of supervised aerobic exercise training (AET) on circulating sRAGE, sTLR4,
Ryan K. Perkins, Corey E. Mazo, James Shadiow, Pallavi Varshney, Edwin R. Miranda, Victoria R. Miranda, Maggie Eisenberg, Jane E. Nakamura, Elif A. Oral, Jacob M. Haus   +9 more
wiley   +1 more source

Lead optimization of AMS-17 identifies AMS-4 as a modulator of inflammasome-driven cocaine-associated neuroinflammation. [PDF]

Biochem Biophys Res Commun
Singh S, Gupta NK, Ahsan AU, Oladapo A, Mata LO, Buch S, Kulkarni A, Periyasamy P.   +7 more
europepmc   +1 more source

Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT‐1 and SURMOUNT‐2 Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8367-8377, September 2026.
ABSTRACT Aims Obesity affects over 800 million people globally and is associated with complications including cardiovascular disease and type 2 diabetes (T2D). Early response to weight loss interventions may help optimize achievement of individual treatment goals.
Alexander Kokkinos, Tina Thethi, Clare J. Lee, Lisa M. Neff, Adam Stefanski, Dachuang Cao, Angel Rodriguez, Amy Bartee   +7 more
wiley   +1 more source

One Week Exposure to a Somatostatin Receptor 2 Antagonist (SSTR2a) Enhances Glucagon Counterregulation to Insulin‐Induced Hypoglycaemia and Does Not Worsen Glycemia in a Male Rat Model of Insulin‐Requiring Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8208-8218, September 2026.
ABSTRACT Introduction Administration of a somatostatin receptor 2 antagonist (SSTR2a) increases glucagon responsiveness to hypoglycaemia in insulin‐treated type 2 diabetes (T2D), but the durability of this effect and the impact of repeated SSTR2a dosing on overall glycaemia in T2D are unclear.
Ninoschka C. D'Souza, Emily G. Hoffman, Sara C. Atherley, Sabrina Champsi, Nadia Aleali, Richard T. Liggins, Owen Chan, Michael C. Riddell   +7 more
wiley   +1 more source

Sodium-glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial. [PDF]

J Diabetes Investig
Takatsuna Y, Ishibashi R, Koshizaka M, Tatsumi T, Baba T, Yamamoto S, Yokote K.   +6 more
europepmc   +1 more source

Prescribing Trajectories in Type 2 Diabetes in the United States, 2019–2024

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8172-8188, September 2026.
ABSTRACT Importance Clinical guidelines for type 2 diabetes (T2D) provide population‐level recommendations, but real‐world treatment patterns evolve dynamically and vary across patients. Understanding longitudinal prescribing trajectories may reveal heterogeneity in care not captured by cross‐sectional analyses.
Tobias S. Lux, Dongkun Lee, Jeff M. Phillips, Julio C. Facelli, Daniel C. Malone, Matthew Wahl, Deepika Reddy, Farrant Sakaguchi, Ramkiran Gouripeddi, Alexander S. Millar, Matthew J. O'Brien, Joshua S. Choi, Jittrapol Sutejitsiri, Kensaku Kawamoto, Polina V. Kukhareva   +14 more
wiley   +1 more source

Cardiovascular Outcomes among New Users of GLP-1 Receptor Agonists Compared with DPP-4 Inhibitors and Sulfonylureas in Kidney Failure. [PDF]

J Am Soc Nephrol
Catanese B, Miller C, Wolf M, Edmonston D.   +3 more
europepmc   +1 more source